



Evolving PBC Management: from Science to Operational Delivery

Date: Thurs 21st Sept, 17:15 – 18:15

Venue: Woods-Scawen Room

- 17:15** PBC: Who needs treating with what in 2017
Prof David Jones
- 17:35** Practicalities of managing 2nd line therapies in clinic
Dr Steve Ryder
- 17:50** Q and A
Prof Jones, Dr Ryder
- 18:00** Discussion: making PBC service delivery work for clinicians and patients
Prof Jones, Dr Ryder, Mrs Collette Thain MBE

Intercept 

UK-NP-PB-0167
Date of Preparation August 2017

This event has been organised and funded by
Intercept Pharma UK and Ireland Ltd.

Evolving PBC Management: from Science to Operational Delivery

As the treatment landscape for patients with PBC evolves, so do the mechanisms through which patients will access these therapies. This educational symposium will address: which PBC patients should be treated with other therapies in addition to UDCA, how clinical practice will have to adapt to manage these patients, and discuss the current and future delivery of PBC service throughout the UK.

An interactive discussion will allow the audience to contemplate how implementation of these services might evolve going forward to meet the needs of patients and clinicians alike.

Speakers

Prof David Jones

Professor of Liver Immunology
Newcastle University

Dr Steve Ryder

Consultant Hepatologist
Nottingham University Hospitals

Mrs Collette Thain, MBE

Chief Executive Officer
PBC Foundation

